U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
REDWOOD CITY, Calif., Feb. 17, 2016 -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report its fourth quarter and full year 2015 financial results on Wednesday, February 24, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at 5:00 p.m. ET (2:00 p.m. PT) to discuss the financial results and provide a corporate update.
Conference Call and Webcast
To access the live conference call on Wednesday, February 24, 2016, at 5:00 p.m. ET (2:00 p.m. PT), please dial (866) 410-4428 (domestic) or (704) 908-0287 (international), conference code 54100990.
To access the live and subsequently archived webcast, visit the investor relations section of the Relypsa website at http://investor.relypsa.com. The webcast will be archived for 30 days following the call.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
